Pharmaceutical and biotech firms are racing to find treatments and vaccines for severe acute respiratory syndrome (SARS), but they worry that by the time they come up with an actual product, the virus may not be the health crisis it appears to be today.
"To be competitive, you need to get into this fast and work fast," said Gordon Cameron, president and chief financial officer of Acambis Inc, the firm supplying small pox vaccine for a national stockpile. "We're certainly looking at SARS. But we're still trying to figure out what the market will be and what the technical hurdles might be. We have to decide shortly. In the next couple months, we either have a program or we don't."
Despite the urgency, much uncertainty remains. Scientists identified the virus causing SARS just a month ago. SARS has infected more than 5,400 people and killed more than 350 since it first appeared in China late last year. But no one knows how fast or how far the virus will spread.
PHOTO: AFP
Few infectious disease specialists believe SARS will disappear. But they can't predict whether SARS will turn into an epidemic, wax and wane with the seasons like the common cold, or remain a relatively rare illness. Even in a best-case scenario, a vaccine or treatment is years away and by the time it is available, many firms worry the sense of urgency may have faded and too few people will want to be vaccinated to justify the hundreds of millions of dollars it takes to develop a drug or a vaccine.
The drug industry is seeking assurances from various federal health agencies that they will streamline the testing process and buy large quantities if a SARS vaccine pans out. Drug companies say they are willing to take the risk for now because the early research into a drug or vaccine is the least expensive part of the process. But developing, testing and then gaining regulatory approval to get a drug to market can cost hundreds of millions of dollars.
"We're not looking for risk-free, nothing we do is risk-free," said Len Lavenda, a spokesman for Aventis Pasteur, the world's biggest vaccine maker, based in Lyon, France. "But we are looking for assurance the government is going to be there in five years."
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the agency is exploring various options for funding research and partnering with industry. But, he said, it is not yet clear that the government would promise to buy a successful vaccine.
The hurdles in developing vaccines are even more considerable than with other types of drugs. Since they are given to healthy people, they must be safer than most other medications. They are often tested in tens of thousands of patients to ferret out uncommon side effects before reaching the market.
Even then problems arise. A vaccine for rotavirus, a stomach illness that kills a million children worldwide each year, was tested in 10,000 infants in 27 clinical trials over 15 years before it was approved. After all that, a rare side effect only emerged later, causing the vaccine to be pulled off the market.
But the industry is plowing ahead. Pharmaceutical giant Merck and Co, based in Whitehouse Station, New Jersey, is screening its stable of drugs to see if any of them will help treat SARS. Merck asked the government for a copy of the virus and dozens of its researchers are beginning work to discover a vaccine.
Chiron Corp, an Emeryville, California, biotech, deciphered the genetic code of one strain of the SARS virus and has 15 scientists searching for a vaccine.
GenVec Inc, a Gaithersburg, Maryland, firm, teamed up with government scientists to hunt for a vaccine based on the same technology it is using to develop an HIV vaccine. GenVec already had a US$10 million contract with the National Institute of Health's (NIH) Vaccine Research Center to work with federal scientists on an AIDS vaccine. As more was learned about the SARS virus, Paul Fischer, GenVec's president and chief executive, suspected its vaccine technology might also be applied to SARS.
That afternoon, GenVec researchers began brainstorming with colleagues at NIH to put together a work plan. Two weeks later, GenVec and NIH hammered out a modified contract in which NIH gave another US$420,000 to start a SARS program. Fischer expects the collaboration to begin making various experimental vaccines in coming weeks that can be tested in animals. If the researchers get lucky, Fischer said, a vaccine could begin human testing in a year.
"In the best of all possible worlds, this virus dies out quickly," Fischer said. "But most people think it will probably return as a seasonal virus. The worst case is that it becomes a terrible epidemic worldwide. In either of the last two scenarios, speed is key."
The history of vaccine development is filled with research efforts that take years to bear fruit. In the 1980s, when researchers first set out to discover a vaccine for HIV, they hoped to have one in hand in a few years. Now, nearly 20 years later, several HIV vaccines are in clinical trials but none has yet reached the market.
Another company in the race is Medarex Inc. Based in Princeton, New Jersey, it joined forces with state researchers in Jamaica Plain and Worcester in search of a molecule that would specifically target the virus and prevent infection in those exposed to the disease.
Dr. Donna Ambrosino, director of the Massachusetts Biologics Lab in Jamaica Plain, part of the University of Massachusetts Medical School, approached Medarex earlier this month with an idea she hopes could control outbreaks of SARS. The state lab was working with Medarex for more than a year on another project. The company genetically engineers mice to produce monoclonal antibodies, hailed as the body's version of guided missiles for their ability to seek out and destroy specific disease-causing cells. In some cases, monoclonal antibody therapies have been easier to develop than vaccines.
"Vaccines are just tough," Ambrosino said. "When you get one that works, it's the best approach. But it takes a long time. That doesn't mean we shouldn't start today. But that's why I feel our effort also needs to begin now."
NO-LIMITS PARTNERSHIP: ‘The bottom line’ is that if the US were to have a conflict with China or Russia it would likely open up a second front with the other, a US senator said Beijing and Moscow could cooperate in a conflict over Taiwan, the top US intelligence chief told the US Senate this week. “We see China and Russia, for the first time, exercising together in relation to Taiwan and recognizing that this is a place where China definitely wants Russia to be working with them, and we see no reason why they wouldn’t,” US Director of National Intelligence Avril Haines told a US Senate Committee on Armed Services hearing on Thursday. US Senator Mike Rounds asked Haines about such a potential scenario. He also asked US Defense Intelligence Agency Director Lieutenant General Jeffrey Kruse
INSPIRING: Taiwan has been a model in the Asia-Pacific region with its democratic transition, free and fair elections and open society, the vice president-elect said Taiwan can play a leadership role in the Asia-Pacific region, vice president-elect Hsiao Bi-khim (蕭美琴) told a forum in Taipei yesterday, highlighting the nation’s resilience in the face of geopolitical challenges. “Not only can Taiwan help, but Taiwan can lead ... not only can Taiwan play a leadership role, but Taiwan’s leadership is important to the world,” Hsiao told the annual forum hosted by the Center for Asia-Pacific Resilience and Innovation think tank. Hsiao thanked Taiwan’s international friends for their long-term support, citing the example of US President Joe Biden last month signing into law a bill to provide aid to Taiwan,
China’s intrusive and territorial claims in the Indo-Pacific region are “illegal, coercive, aggressive and deceptive,” new US Indo-Pacific Commander Admiral Samuel Paparo said on Friday, adding that he would continue working with allies and partners to keep the area free and open. Paparo made the remarks at a change-of-command ceremony at Joint Base Pearl Harbor-Hickam in Hawaii, where he took over the command from Admiral John Aquilino. “Our world faces a complex problem set in the troubling actions of the People’s Republic of China [PRC] and its rapid buildup of forces. We must be ready to answer the PRC’s increasingly intrusive and
STATE OF THE NATION: The legislature should invite the president to deliver an address every year, the TPP said, adding that Lai should also have to answer legislators’ questions The Chinese Nationalist Party (KMT) yesterday proposed inviting president-elect William Lai (賴清德) to make a historic first state of the nation address at the legislature following his inauguration on May 20. Lai is expected to face many domestic and international challenges, and should clarify his intended policies with the public’s representatives, KMT caucus secretary-general Hung Meng-kai (洪孟楷) said when making the proposal at a meeting of the legislature’s Procedure Committee. The committee voted to add the item to the agenda for Friday, along with another similar proposal put forward by the Taiwan People’s Party (TPP). The invitation is in line with Article 15-2